Eli Lilly Receives FDA Warning Letter - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Eli Lilly Receives FDA Warning Letter

ePT--the Electronic Newsletter of Pharmaceutical Technology

Eli Lilly has received an FDA Warning Letter because of a “misleading” image of a multicolored brain scan that appeared on the company’s website for the diagnostic Positron Emission Tomography (PET) tracer, Amyvid. Amyvid is indicated for PET brain scans to review β-amyloid neuritic plaque density in patients who are being evaluated for Alzheimer’s Disease.

According to FDA, the use of the colored brain image classifies as misbranding because Amyvid’s product labeling states that Amyvid images must be displayed and reviewed in black and white. Black and white scale “with the maximum intensity of the scales set to the maximum intensity of all the brain pixels” is necessary for accurately reviewing the scans. Amyvid’s product information also includes several black and white example scans to illustrate interpretation. The use of a color image suggests that the scans can be displayed and interpreted in color.

“While many PET images are displayed and reviewed in color, Amyvid scans...must be displayed and reviewed using a black and white scale,” states FDA’s Warning Letter. “Additionally, the [product insert] does not provide instructions for estimating β-amyloid neuritic plaque density using a color scale with Amyvid. Therefore, use of color PET scan image of a brain in Amyvid promotional materials is misleading.”

The image has also been used in other marketing materials, including in the commercial exhibit hall of the American Academy of Neurology annual meeting, which was held in New Orleans, April 23–26, 2012.

Eli Lilly has not yet issued a press statement in response to the Warning Letter.

Amyvid was approved by FDA in April 2012, but received a complete response letter from FDA in March 2011 because of concerns about how to review and interpret Amyvid scans. In response, Eli Lilly created a specific training program.

Related Articles

PhRMA’s Research and Hope Awards Unveiled


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here